Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis
Hui Xu, Zhinuan Hong, Ye Lin, Sunkui Ke, Zhen Chen, Shuhan Xie, Dinghang Chen, Kaiming Peng, Peipei Zhang, Mingduan Chen, Ziyang Han, Jihong Lin, Shuchen Chen, Jinxin Xu, Jinbiao Xie, Mingqiang Kang

TL;DR
This study examines the effects of delaying surgery after immunotherapy for esophageal cancer, finding that a longer wait may be acceptable without worsening outcomes.
Contribution
The study evaluates the impact of prolonged intervals to surgery after immunotherapy for esophageal cancer, providing insights into treatment timing.
Findings
Prolonged interval group showed higher pCR but not statistically significant.
No significant differences in DFS or OS between the groups.
No major differences in surgical outcomes or complications.
Abstract
Neoadjuvant chemoimmunotherapy (nICT) has emerged as a novel and promising treatment model for esophageal squamous cell carcinoma (ESCC). However, the optimal interval to esophagectomy after nICT remains unclear. This study aimed to explore the impact of a prolonged interval (7–10 weeks) on short‐ and long‐term outcomes compared to the standard interval (4–6 weeks). This was a multicenter retrospective cohort analysis, including three centers. Patients were diagnosed with locally advanced ESCC (cT3‐4a or cN+) and received radical resection after at least one cycle of nICT. The primary outcomes were pathological response, disease‐free survival (DFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was utilized to balance the baseline characteristics. One hundred and seventy patients were included in the study, with 123 in the standard interval group and 47…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEsophageal Cancer Research and Treatment · Esophageal and GI Pathology · Gastric Cancer Management and Outcomes
